Benzinga

Benzinga

Benzinga

sábado, septiembre 05

ADMA Biologics Inc

ADMANASDAQ
Trade with Public
Trade with Public
$9.62
0.040.42%
al cierre: Sep 4, 5:00 PM EST
$9.58
-0.0445-0.46%
After hour: 7:29 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

ADMA Biologics Financials

ADMA Biologics (ADMA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est

ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.
Benzinga Newsdesk

PRO
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of $0.14 per share from
Benzinga Newsdesk

PRO
ADMA Biologics Withdraws Long-Term Guidance To Reflect Evolving U.S. Plasma Products And IG Market Competitive Dynamics

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
ADMA Biologics Sees FY2026 Sales $530.000M-$560.000M vs $632.367M Est

ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $530.000 million-$560.000 million vs $632.367 million analyst estimate.
Benzinga Newsdesk

PRO
ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.20 by 15 percent. This is a 21.43 percent increase over earnings of $0.14 per share from the
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved